On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax COVID-19 vaccine candidate, in Japan.

Additionally, Takeda dosed the first participants in a Phase 1/2 clinical trial to test the immunogenicity and safety of Novavax vaccine candidate in the Japanese population.